Cargando…
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
BACKGROUND: While radiation and chemotherapy are primarily purposed for their cytotoxic effects, a growing body of preclinical and clinical evidence demonstrates an immunogenic potential for these standard therapies. Accordingly, we sought to characterize the immunogenic potential of radiation and c...
Autores principales: | Kowalczyk, Joshua T, Fabian, Kellsye P, Padget, Michelle R, Lopez, Diana C, Hoke, Austin TK, Allen, Clint T, Hermsen, Mario, London,, Nyall R, Hodge, James W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791467/ https://www.ncbi.nlm.nih.gov/pubmed/36564129 http://dx.doi.org/10.1136/jitc-2022-005752 |
Ejemplares similares
-
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
por: Fabian, Kellsye P, et al.
Publicado: (2021) -
Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing
por: Wolfson, Benjamin, et al.
Publicado: (2021) -
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
por: Fabian, Kellsye P, et al.
Publicado: (2020) -
Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells
por: Hoke, Austin T.K., et al.
Publicado: (2021) -
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions
por: Speetjens, Frank M, et al.
Publicado: (2022)